Literature DB >> 17503728

Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.

F Rolling1, Guylène Le Meur, Knut Stieger, Alexander J Smith, Michel Weber, Jack Yves Deschamps, Delphine Nivard, Alexandra Mendes-Madeira, Nathalie Provost, Yann Péréon, Yan Cherel, Robin R Ali, Christian Hamel, Philippe Moullier, Fabienne Rolling.   

Abstract

Previous studies have tested gene replacement therapy in RPE65 deficient dogs using recombinant adeno-associated virus 2/2 (rAAV2/2), -2/1 or -2/5 mediated delivery of the RPE65 gene. They all documented restoration of dark- and light-adapted ERG responses and improved psychophysical outcomes. Use of a specific RPE65 promoter and a rAAV vector that targets transgene expression specifically to the retinal pigmented epithelium (RPE) may, however, provide a safer setting for the long-term therapeutic expression of RPE65. Subretinal injection of rAAV2 pseudotyped with serotype 4 (rAAV2/4) specifically targets the RPE. The purpose of our study was to evaluate a rAAV2/4 vector carrying a human RPE65cDNA driven by a human RPE65 promoter, for the ability to restore vision in RPE65-/- purebred Briard dogs. Recombinant rAAV2/4 and rAAV2/2 vectors containing similar human RPE65 promoter and cDNA cassettes were generated and administered subretinally in 8 affected dogs, ages 8 to 30 months (n = 6 with rAAV2/4, n = 2 with rAAV2/2). Although fluorescein angiography and OCT examinations displayed retinal abnormalities in treated retinas, electrophysiological analysis demonstrated that restoration of rod and cone photoreceptor function started as soon as 15 days post-injection, reaching maximal function at 3 months post-injection, and remaining stable thereafter in all animals treated at 8 to 11 months of age. As assessed by the ability of these animals to avoid obstacles in both dim and normal light, functional vision was restored in the treated eye, while the untreated contralateral eye served as an internal control. The dog treated at a later age (30 months) did not recover retinal function or vision, suggesting that there might be a therapeutic window for the successful treatment of RPE65 -/- dogs by gene replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17503728

Source DB:  PubMed          Journal:  Bull Mem Acad R Med Belg        ISSN: 0377-8231


  9 in total

1.  Histopathology and functional correlations in a patient with a mutation in RPE65, the gene for retinol isomerase.

Authors:  Vera L Bonilha; Mary E Rayborn; Yong Li; Gregory H Grossman; Eliot L Berson; Joe G Hollyfield
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-28       Impact factor: 4.799

2.  Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium.

Authors:  Sung Wook Park; Jin Hyoung Kim; Woo Jin Park; Jeong Hun Kim
Journal:  J Vis Exp       Date:  2015-08-07       Impact factor: 1.355

Review 3.  RPE65: role in the visual cycle, human retinal disease, and gene therapy.

Authors:  Xue Cai; Shannon M Conley; Muna I Naash
Journal:  Ophthalmic Genet       Date:  2009-06       Impact factor: 1.803

4.  AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs.

Authors:  Virginie Pichard; Nathalie Provost; Alexandra Mendes-Madeira; Lyse Libeau; Philippe Hulin; Kizito-Tshitoko Tshilenge; Marine Biget; Baptiste Ameline; Jack-Yves Deschamps; Michel Weber; Guylène Le Meur; Marie-Anne Colle; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2016-02-09       Impact factor: 11.454

Review 5.  Promising and delivering gene therapies for vision loss.

Authors:  Livia S Carvalho; Luk H Vandenberghe
Journal:  Vision Res       Date:  2014-08-02       Impact factor: 1.886

6.  Adeno-associated virus-mediated gene transfer.

Authors:  Arun Srivastava
Journal:  J Cell Biochem       Date:  2008-09-01       Impact factor: 4.429

Review 7.  An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.

Authors:  Wei Chiu; Ting-Yi Lin; Yun-Chia Chang; Henkie Isahwan-Ahmad Mulyadi Lai; Shen-Che Lin; Chun Ma; Aliaksandr A Yarmishyn; Shiuan-Chen Lin; Kao-Jung Chang; Yu-Bai Chou; Chih-Chien Hsu; Tai-Chi Lin; Shih-Jen Chen; Yueh Chien; Yi-Ping Yang; De-Kuang Hwang
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 8.  Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration.

Authors:  Kai Kaarniranta; Debasish Sinha; Janusz Blasiak; Anu Kauppinen; Zoltán Veréb; Antero Salminen; Michael E Boulton; Goran Petrovski
Journal:  Autophagy       Date:  2013-04-09       Impact factor: 16.016

9.  A new rat model of treatment-naive quiescent choroidal neovascularization induced by human VEGF165 overexpression.

Authors:  Shan Liu; Antje K Biesemeier; Alexander V Tschulakow; Harsh V Thakkar; Sylvie Julien-Schraermeyer; Ulrich Schraermeyer
Journal:  Biol Open       Date:  2020-06-11       Impact factor: 2.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.